3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Neoplasms
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Interventions
fludarabine phosphate
23
Peripheral Blood Stem Cell Transplantation
19
Whole-Body Irradiation
18
Mycophenolic Acid
16
Cyclophosphamide
15
Busulfan
15
Tacrolimus
14
Antilymphocyte Serum
14
Cyclosporine
11
Melphalan
10
Rituximab
9
Methotrexate
9
Etoposide
8
romidepsin
6
Flow Cytometry
6
Filgrastim
6
Vorinostat
5
Dexamethasone
5
thymoglobulin
4
fludarabine
4
Sirolimus
4
Granulocyte Colony-Stimulating Factor
4
Carboplatin
4
Calcium Dobesilate
4
Bexarotene
4
Alemtuzumab
4
Thiotepa
3
Therapeutics
3
Radiotherapy
3
Panobinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, T-Cell, Cutaneous
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts